297 related articles for article (PubMed ID: 19137020)
1. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
2. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
3. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm.
Royer-Pokora B; Busch M; Beier M; Duhme C; de Torres C; Mora J; Brandt A; Royer HD
Hum Mol Genet; 2010 May; 19(9):1651-68. PubMed ID: 20106868
[TBL] [Abstract][Full Text] [Related]
4. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
[TBL] [Abstract][Full Text] [Related]
5. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
[TBL] [Abstract][Full Text] [Related]
6. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
7. Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children.
Haruta M; Arai Y; Watanabe N; Fujiwara Y; Honda S; Ohshima J; Kasai F; Nakadate H; Horie H; Okita H; Hata J; Fukuzawa M; Kaneko Y
Cancer Sci; 2012 Jun; 103(6):1129-35. PubMed ID: 22409817
[TBL] [Abstract][Full Text] [Related]
8. Cancer. Converging on beta-catenin in Wilms tumor.
Nusse R
Science; 2007 May; 316(5827):988-9. PubMed ID: 17510350
[No Abstract] [Full Text] [Related]
9. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
10. WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?
Corbin M; de Reyniès A; Rickman DS; Berrebi D; Boccon-Gibod L; Cohen-Gogo S; Fabre M; Jaubert F; Faussillon M; Yilmaz F; Sarnacki S; Landman-Parker J; Patte C; Schleiermacher G; Antignac C; Jeanpierre C
Genes Chromosomes Cancer; 2009 Sep; 48(9):816-27. PubMed ID: 19530245
[TBL] [Abstract][Full Text] [Related]
11. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
[TBL] [Abstract][Full Text] [Related]
12. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
13. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
Ruteshouser EC; Robinson SM; Huff V
Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
[TBL] [Abstract][Full Text] [Related]
14. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
15. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target.
Pode-Shakked N; Harari-Steinberg O; Haberman-Ziv Y; Rom-Gross E; Bahar S; Omer D; Metsuyanim S; Buzhor E; Jacob-Hirsch J; Goldstein RS; Mark-Danieli M; Dekel B
Oncogene; 2011 Apr; 30(14):1664-80. PubMed ID: 21472018
[TBL] [Abstract][Full Text] [Related]
16. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
[TBL] [Abstract][Full Text] [Related]
17. LMP1 antagonizes WNT/β-catenin signalling through inhibition of WTX and promotes nasopharyngeal dysplasia but not tumourigenesis in LMP1(B95-8) transgenic mice.
QingLing Z; LiNa Y; Li L; Shuang W; YuFang Y; Yi D; Divakaran J; Xin L; YanQing D
J Pathol; 2011 Apr; 223(5):574-83. PubMed ID: 21394719
[TBL] [Abstract][Full Text] [Related]
18. The expression of the insulin-like growth factor II, JIP-1 and WT1 genes in porcine nephroblastoma.
Engström W; Granerus M
Anticancer Res; 2009 Dec; 29(12):4999-5003. PubMed ID: 20044608
[TBL] [Abstract][Full Text] [Related]
19. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
[TBL] [Abstract][Full Text] [Related]
20. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
